In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 351 to 375 of 387

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]	Technology appraisal guidance	10 February 2027
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]	Technology appraisal guidance	13 May 2027
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]	Highly specialised technology	17 March 2027
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351]	Technology appraisal guidance	TBC
Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]	Technology appraisal guidance	28 July 2025
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]	Technology appraisal guidance	TBC
Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713	Technology appraisal guidance	TBC
Topical tapinarof for treating mild to severe plaque psoriasis ID6712	Technology appraisal guidance	TBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]	Technology appraisal guidance	2 December 2026
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]	Technology appraisal guidance	TBC
Transvaginal radiofrequency ablation for symptomatic uterine fibroids	HealthTech guidance	TBC
Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]	Technology appraisal guidance	13 January 2027
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]	Technology appraisal guidance	TBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	TBC
Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]	Technology appraisal guidance	TBC
Unilateral MRI-guided focused ultrasound thalamotomy for medication-refractory essential tremor	HealthTech guidance	17 December 2026
Upadacitinib for treating giant cell arteritis [ID6299]	Technology appraisal guidance	14 October 2026
Vamikibart for treating uveitic macular oedema ID6671	Technology appraisal guidance	TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]	Technology appraisal guidance	TBC
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]	Technology appraisal guidance	TBC
Venous thromboembolism in over 16s : aspirin following orthopaedic surgery (update)	NICE guideline	TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]	Technology appraisal guidance	TBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [TSID12099]	Technology appraisal guidance	TBC

Results per page

10
25
50
All